Study Design
This study is being conducted in three phases (i.e., pre-implementation, implementation, & post-implementation) using a mixed-methods hybrid type II effectiveness-implementation design. Two implementation frameworks: the Consolidated Framework for Implementation Research (CFIR) and the Reach Effectiveness Adoption Implementation and Maintenance (RE-AIM) guide this study. Figure 1 provides an overview of the study design including the randomization of the 30 study sites of which 15 will be in the practice facilitation enhanced (PF + TASSH) arm and the remaining 15 will be in the self-directed control (TASSH only) arm. During the pre-implementation phase we developed a context-specific PF strategy based on three key study-related activities: 1) data from a CFIR guided mapping exercise conducted prior to study funding; 2) discussions with Steering Committee members, and 3) rapid ethnography of the clinical workflows at the PHCs along with interviews conducted with patients and healthcare workers. The data from the CFIR mapping exercise and discussions with the Steering Committee members informed the need to conduct a rapid ethnography to better understand the clinical workflow for PLWH with hypertension as well as patients’ and healthcare providers’ perspectives on hypertension treatment within PHCs.
For the implementation phase, we will conduct a cluster randomized control trial (RCT) of 30 PHCs and 960 HIV + patients with uncontrolled hypertension. The aim of this implementation phase is to compare the effect of PF versus a self-directed condition (i.e., receipt of the information on TASSH without PF) on systolic BP reduction at 12 months. During the post-implementation phase, the RE-AIM framework will compare the effect of PF versus self-directed condition on adoption and sustainability of TASSH at 12 and 24 months respectively. Additionally, the mediators for the adoption and sustainability of TASSH will be assessed at 12 and 24 months. This study is approved by the institutional review boards (IRB) of New York University Grossman School of Medicine and the Nigerian Medical Research Institute. The study is registered at Clincialtrials.gov (NCT04704336).
Description of TASSH-HIV integration protocol
The procedure for delivering TASSH within PHCs for PLWH is based on a four-step approach for Identifying, Counseling, Treating, and Referring (ICTR) and is defined as: i) identifying PLWH patients with uncontrolled hypertension by taking the patient’s CVD history, measuring their BP, and assessing their cardiovascular (CV) risk; ii) initiating lifestyle counseling for PLWH with uncontrolled hypertension on adopting healthy behaviors; iii) treating PLWH with uncontrolled hypertension by prescribing medication using Nigeria’s hypertension treatment protocol, and iv) referring PLWH with complicated hypertension to physicians for additional care. Complicated hypertension is defined as PLWH with BP > 180/110 or those with a history of stroke, diabetes, chronic kidney disease, or heart failure. Figure 2 provides an overview of the TASSH intervention and includes the protocol for the interventionists (i.e., HIV nurses and CHEWs) to deliver the intervention components using the 5A’s counseling strategy (Ask, Assess, Advise, Assist, and Arrange). The 5A’s have been used for health behavior change for patients in previous TASSH studies (14, 23) and other health outcomes such as smoking cessation (39) and weight loss (40).
Practice facilitation (PF) implementation strategy
This study will evaluate PF’s effect on the clinical outcomes (i.e., reduction in systolic BP) for PLWH with uncontrolled hypertension as well as the adoption and sustainability of the TASSH intervention as part of Lagos State’s primary healthcare delivery network. To meet these study goals, we have developed a context-specific PF approach for integrating TASSH into HIV care at the PHCs by a) organizing and engaging a Steering Committee consisting of key stakeholders who will provide leadership support for the adaptation and integration of TASSH into PHCs; b) applying a train-the-trainer (TTT) model (11, 23) wherein experienced nurses from the Directorate of Nursing serve as practice outreach facilitators (POFs); and c) training the interventionists on the TASSH protocol for BP measurement, CV risk assessment, initiation of treatment with antihypertensive medications, and referral of complicated cases.
Table 1 provides specific details of the key components of the PF strategy for the 15 study sites randomized to the PF + TASSH arm. Briefly, these PF strategy components consist of: a) POF training on using a coaching strategy developed specifically for the TASSH intervention to Enhance, Engage, and Evaluate [hereinafter the “3 Es”] the interventionists’ capacity to perform the TASSH duties; b) training the interventionists on delivering the TASSH protocol i.e. ICTR + 5A’s; and c) creating a dual community learning and engagement environment for the implementers (POFs), the interventionists, and the PLWH with uncontrolled hypertension.
Table 1
Overview of PF Strategy components
COMPONENT
|
OVERVIEW
|
A) Training the POFs to use the 3 E’s to support the interventionists.
|
POFs will be trained to coach and support the HIV nurses in delivering TASSH as follows:
• Engage the interventionists via monthly phone calls to address barriers in performing their TASSH duties.
• Enhance the interventionists ability to sustain TASSH via on-site quarterly visits to observe and supervise them in their duties.
• Evaluate the interventionist during onsite supervision and in using the learning community (WhatsApp).
|
B) Training the interventionists on the TASSH protocol (ICTR + 5 A’s).
|
HIV nurses will be trained to Identify, Counsel, Treat, and Refer (ICTR) PLWH with uncontrolled hypertension using the 5 A’s counseling strategy (Ask, Assess, Advise, Assist, and Arrange) [See Fig. 2 for more details on the ICTR + 5A’s approach].
|
C) Creating a community learning & engagement environment.
|
• Developing a community learning environment will support learning opportunities for the POFs and the interventionists via the sharing of structured messages via WhatsApp. These messages will include content on BP measurement techniques, counseling skills, as well as the sharing of hypertension education materials. Information on tips on ICTR will also be shared.
• Promoting a community engagement and support environment for patients by training the interventionists to identify patient’s preferences for follow-up (i.e., frequency of reminders/ phone calls) to check-up on the patient’s health and welfare.
|
Conceptual Frameworks
As previously noted, the study is guided by CFIR (for the pre-implementation phase) and RE-AIM (for the implementation and post-implementation phases). A robust framework for identifying and operationalizing context-relevant barriers and facilitators for intervention adaptation (41), the five domains of CFIR (i.e., intervention characteristics, outer setting, inner setting, characteristics of individuals, and the implementation process) provided pre-study data which informed the adaptation of the PF strategy for embedding the TASSH intervention within PHCs. Additional details on the use of CFIR for mapping the implementation readiness of the PHCs to integrate the TASSH intervention are published elsewhere (42)
The RE-AIM framework will inform the evaluation of the effectiveness of the TASSH intervention on BP reduction as well as the adoption and sustainability of the intervention throughout the PHCs. RE-AIM consists of five domains and has been used to measure several evidence-based interventions including diabetes self-management (43, 44), smoking cessation (44), and physical activity (43). In this study, the five domains of the RE-AIM framework will be applied as follows: Reach (number of sites and people in the TASSH intervention), Effectiveness (impact of TASSH intervention on BP outcomes), Adoption (number of sites and providers using the TASSH intervention), Implementation (extent of intervention delivery) and Maintenance (sustainability of outcomes). Figure 1 illustrates the conceptual model of how this study applies CFIR and RE-AIM to integrate hypertension management into the HIV care continuum in the PHCs.
Study setting
The study will take place in Lagos, the most populous state in Nigeria with 22 million people (45). Implementation will occur in 30 PHCs, which are the major system for healthcare delivery including HIV treatment and care throughout Nigeria. The Nigerian Institute for Medical Research (NIMR) will select the 30 PHCs from 67 PHCs registered with the Lagos State Primary Healthcare Board with each site recruiting an average of 32 patients for a total of 960 patients for the study.
Ethical considerations
Institutional Review Board (IRB) Approvals for this study was obtained from the NYU Grossman School of Medicine (NYUGSOM) and the Nigerian Institute of Medical Research (NIMR). The trial is also registered at ClinicalTrials.gov (NCT04704336).
Enrollment, randomization, and allocation
Randomization will occur at the PHC level. All 30 PHCs enrolled in the study will begin the study as part of the pre-implementation phase for the first 12 months of the study, after which they will be randomly assigned to either the PF + TASSH arm (N = 15) or the TASSH only arm (N = 15). Once randomized, the PHCs will participate in the implementation phase (i.e., trial period) for 12 months, followed by an additional 12-month post-implementation period to assess the sustainability of the intervention. Every 6 months for 30 months, randomization will occur in 5 cohorts of 6 PHCs and will be stratified by cohort to ensure balance over time. Once recruitment is completed for each cohort, the PHCS will be randomized in a 1:1 ratio to either the PF + TASSH arm or the TASSH only arm. The sequence of randomization will be generated by a statistician and kept in a secure electronic format inaccessible to study sites, following CONSORT guidelines. Sites will be informed of their randomization group by telephone. In addition, due to the nature of the intervention, it is impossible to blind the patients, lay health advisors, and the study coordinators to the group assignment, therefore only the data analysts will remain blinded to treatment assignment until all data have been collected and the database is locked.
Recruitment
Primary care practices
Primary health centers (PHCs) which are responsible for providing HIV care and treatment will be recruited and selected by the Nigerian Institute of Medical Research (NIMR), which has well-established linkages to the Lagos State AIDS Council Agency (LSACA) and the Lagos State Primary Healthcare Board with its network of 67 PHCs. Out of the 67 PHCs, we will recruit 30 PHCs. Eligibility of the 30 PHCs will include being in geographically distinct areas from one another, with an equal urban to rural mix in two arms. Once a clinic agrees to participate in the study, clinic director will sign a memorandum of understanding (MOU) with NIMR and will be asked to identify HIV nurses to be trained.
Patients
We will recruit an average of 32 people living with HIV (PLWH) from each of the 30 PHCs selected from the study. Research coordinators working with the Interventionists will recruit PLWH meeting the following eligibility criteria: a) patient receiving HIV treatment care at the selected PHC; b) an adult aged 40 years and older; c) have a diagnosis of hypertension with uncontrolled blood pressure, i.e., BP is 140–179/90–100 mm Hg; and d) able to provide consent. Working with the research coordinators, interventionists will identify PLWH who meet the inclusion criteria and provide a contact number to interested PLWH to follow up with the research coordinator. Research coordinators will inform interested PLWH of their 50–50 chance of being randomized to the PF + TASSH or the TASSH only arm of the study. The rationale for including only patients with uncomplicated hypertension is based on the World Health Organization’s CVD treatment guidelines (46), which mandate patients with stroke, heart failure, and kidney disease be referred to physicians for management. Patients will be excluded for the following reasons: a) having a BP > 180/110mm Hg; b) having a history of chronic kidney disease, heart disease, diabetes or stroke, pregnancy; c) unable to provide informed consent; and d) refusing to participate in the study.
Practice outreach facilitators
NIMR will work with the Lagos State Directorate of Nursing to recruit the practice outreach facilitators (POFs). The Directorate of Nursing is responsible for overseeing the training, planning, and evaluation of capacity-building programs for nurses in Lagos State and has a network of senior nursing officers with extensive clinical and managerial experience, including working with primary care practices as trainers. We will hire 5 senior nurses to serve as practice facilitators to the 15 HIV clinics randomized to the PF intervention group (one per 3 clinics). The decision to recruit senior nurses to train the Interventionists in implementing TASSH is a sustainable model because traditionally, in Lagos State, nursing officers are responsible for training nurses within the primary care practices. Consequently, recruiting nursing officers as POFs will be key to ensuring the adoption and sustainability of TASSH.
Training approach
HIV nurses, CHEWs, and POFs are all trained on the TASSH protocol. POFs are further trained on coaching strategies (3 Es) to help the Interventionists implement TASSH. The duration of all training will be three full days. Following the initial training, supplemental booster training will take place every 6 months for the duration of the trial period. Table 2 provides an overview of the training approach for the POFs, HIV nurses, and CHEWs. All training sessions will be audiotaped and videotaped for future use by the trainees. All trainees will complete a pre-and post-test on all study materials such that adequate training will be based on satisfactory completion of the study materials after training. Finally, we will employ the ‘see one, do one and teach one strategy (11, 23) to make sure that trainees acquire the necessary skills. Finally, regarding training on the referral of study participants to the PHCs, the Interventionists will be required to use electronic data capture which will be tracked for completion regularly.
Table 2
Interventionist
|
Training Components
|
Training Timing and Frequency
|
POFs (train-the-trainer model)
|
3E’s (to oversee intervention implementation)
|
Booster training sessions will occur every 6 months after the initial training date.
|
TASSH Protocol (counseling using 5A’s and drug treatment)
|
HIV Nurses/ CHEWs
|
TASSH Protocol (counseling using 5A’s and drug treatment)
|
Booster training sessions will occur every 6 months after the initial training date.
|
Identify, Counsel, Treat, Refer
|
Online Learning Communities
(using WhatsApp to increase engagement)
|
Ongoing
|
Intervention and control conditions
For the PF + TASSH (implementation-intervention) arm, compliance with study protocol will be based on the: a) training of the Interventionists on BP measurements, counseling of eligible participants using the 5 A’s, and referral of studyparticipants for further care based on the referral system within the PHCs; and b) training of the POFs on using the 3 E’s to support the Interventionists. Each POF will be required to work with their assigned HIV clinics for 12 months. Over the 12-month period, each POF will conduct 13 site visits to the HIV clinics (2 in the first month, and then monthly thereafter) plus monthly peer-to-peer telephone support calls to the Interventionists.
For the TASSH only (control) arm, Interventionists will be trained on BP measurements, counseling of eligible participants using the 5 A’s, and referral of the participants for further care based on the referral system within the PHCs. The TASSH only arm will not receive practice facilitation support from the POFs. Participants attending PHC randomized to the TASSH only arm will receive standard care offered by that facility.
Primary Outcome
The primary outcome is a change in systolic BP (SBP) from baseline to 12 months of TASSH Implementation. The SBP reduction in patients will be assessed as mean change in systolic BP from baseline to 12 months. Blood pressure will be taken with a valid automated BP device as follows: at baseline, three BP readings will be taken by trained research coordinators using an automated BP monitor with the participant seated comfortably for 5 minutes prior to the measurements. The average of three BP readings will be used as the measure for each visit. The same procedure will be followed at the 12-month study visit. Uncontrolled BP will be defined in accordance with the Nigerian healthcare policy and WHO for CVD treatment guidelines as the average clinic systolic BP > 140 mmHg or diastolic BP > 90 mmHg. Adopting these guidelines currently instituted within the Nigerian healthcare system will ensure sustainability of the proposed study’s procedures
Secondary Outcomes
There are two secondary outcomes for this study: to evaluate the rate of adoption and sustainment of the TASSH intervention across the PHCs at 12 and 24 months respectively. The rate of adoption of TASSH is defined as the proportion of patients who are correctly diagnosed with hypertension, received lifestyle counseling, and antihypertensive treatment from the interventionists. For this purpose, adoption will be assessed by the following measures: 1) the number of hypertensive patients diagnosed correctly by the nurses using the WHO CVD risk assessment; 2) proportion of patients with hypertension who received lifestyle counseling from the nurses; and 3) proportion of patients for whom the interventionists initiated treatment with antihypertensive medications. In order to assess this measure, the interventionist will complete a questionnaire inquiring about the number of patients with uncontrolled hypertension who received medication treatment and lifestyle counseling. For this purpose, all interventionists will be required to keep an attendance log sheet for their patients’ visits.
Sustainability of TASSH is defined as the maintenance of TASSH uptake at the PHCs at 24 months (one year after the end of the TASSH intervention). Sustainability will be assessed quantitatively, similar to adoption, and qualitatively, based on interviews with interventionists and clinic leadership at 24 months. Two research coordinators will conduct the interviews with two interventionists, and one key leadership personnel at each clinic. The interviews will be guided by CFIR and inquire about attitudes regarding the implementation of TASSH, barriers, facilitators, and implications for scalability. All interviews will be recorded, transcribed, and analyzed with NVIVO Version 11.
Mediators of TASSH
We will use several measures to assess the mediators of TASSH via self-report. The mediators are based on the constructs of the CFIR framework including inner setting characteristics of the PHCs, intervention characteristics, and implementation process measures. Inner setting measures include implementation climate, implementation leadership, and the organizational culture domain of the organizational social context scale. Implementation climate will be assessed with the Implementation Climate Scale that measures shared perceptions of the policies, practices, procedures, and behaviors that are expected, supported, and rewarded to facilitate the effective implementation of evidence-based practices. Implementation leadership will be assessed using the Implementation Leadership Scale (ILS) – a brief 12-item measure with four subscales: proactive Leadership, knowledgeable leadership, supportive leadership, and perseverant leadership. We will use the organizational culture domain of the Organizational Social Context Scale – a 15-item proficiency subscale– to evaluate the practice capacity proficiency level of the PHCs. Proficient organizational cultures are those characterized by shared norms and expectations that the interventionists are skilled service providers, and have current knowledge of the TASSH protocol.
Intervention characteristics will be measured using the evidence scale of the Organizational Readiness to Change Assessment tool, which evaluates the strength of the evidence for the proposed change or innovation (47). For implementation process measures, we will use the external change agent support and the facilitation scale of the Organizational Readiness to Change Assessment (ORCA) tool (47). The external change agent support is a 3-item tool that evaluates support provided by external facilitators, the expectations about performance and improvement, and the ways to achieve the goal of the project. The Facilitation Scale is an 8-item tool that evaluates organizational capacity to facilitate change. Table 3 provides a list of all study measures, including the data source for each and the timing of administration.
Table 3
Construct
|
Measures
|
Data Source
|
Timing of Administration
|
Pre-implementation phase
|
Intervention characteristics
|
• Organizational readiness to change (12-item Evidence Scale)
|
• Steering committee and staff surveys
|
Baseline
|
Inner setting
|
• Implementation Climate Scale
• Implementation Leadership Scale
• Organizational Culture domain of the Organizational Social Context Scale
|
• Semi-structured interviews with Key Stakeholders
• Steering committee and staff surveys
|
Baseline
|
Implementation process
|
• External Change Agent Support tool (3-item tool)
• Organizational Readiness to Change Assessment (Facilitation Scale-8 item)
|
• Steering committee and staff surveys
|
Baseline
|
Implementation phase
|
Systolic BP reduction (primary outcome)
|
• Automated BP Monitor (according to WHO guidelines)
• Participant characteristics
|
• Clinic patient medical records
|
Baseline and 12 months
|
Adoption of TASSH (secondary outcome)
|
• CVD Risk Assessment
• Lifestyle Counseling
• Medication Titration
|
• Nurse interviews and questionnaires
• Attendance log sheet patient visits
|
12 months
|
Post-implementation phase
|
Sustainability of TASSH (secondary outcome)
|
• CVD Risk Assessment
• Lifestyle Counseling
• Medication Titration
|
• Nurse interviews and questionnaires
• Attendance log sheet patient visits
|
24 months
|
Statistical approach
Power considerations and sample size
The TASSH intervention will be delivered through group sessions at clinics and thus the appropriate design is a cluster-randomized trial where the unit of randomization is the clinic. There are two important study design features: the number of PHCs, and the number of participants per PHCs. Specifically, the participants will be nested (grouped) within the PHCs. From our previous work implementing TASSH, we can expect an effect size of approximately 3.5 mmHg, with a standard deviation of approximately 12 mmHg; this leads to a standardized effect size of approximately 0.3. Thus, we estimate sample sizes for a range of small to moderate effect sizes (d = .30 to .50) for this intervention, assuming an average cluster size of about 30 participants per PHC, and an ICC of between .02 and .05 at the significance level of 0.05 (two-sided test). Based on these assumptions and calculations we have established recruitment goals of 30 clinics (15 in each arm) with 32 participants per PHC. This yields a total sample size of 30 x 32 = 960 participants, providing more than 90% power to detect a small effect size of 0.3 with a conservative assumption of ICC = 0.04. This sample size calculation has included adjustment for up to 20% attrition of the study sample.
General analytical approach
All data will be summarized and presented in tabular and graphical format, using means, standard deviations, medians, and ranges for continuous variables and proportions for categorical variables. We will assess balance for baseline characteristics according to randomized treatment assignment. Analyses will be conducted according to the principle of intention-to-treat, in which every PHC is analyzed according to the assigned intervention, regardless of the condition received.
Primary outcome analysis
The analysis will consist of a repeated-measures mixed-effects model for systolic BP (SBP), with fixed effects for time and intervention arm, and random effects for PHC. We will include an interaction term for the intervention arm and time; this, if non-zero, will indicate that the degree of change of SBP over time differs for those in the practice facilitation intervention compared to those in the self-directed condition. We will also assess whether adjustment for any baseline characteristics is necessary, including such adjustments based on the change-in-estimate criteria.
Secondary outcomes analysis
We will evaluate the difference between the intervention arms in the adoption and sustainability of the TASSH program at 12 and 24 months. We will use a multi-level mixed model using an unstructured covariance matrix, with the outcomes defined as the proportion of participants within a PHC who were diagnosed with hypertension, received lifestyle counseling and treatment for hypertension at 12 months (adoption), and the proportion of participants within a PHC who have received screening, counseling and hypertension treatment at 24 months (sustainability). For adoption, the analysis will have one within-person factor: time (baseline and 12-month coded naturally as months [0 and 12]) and one primary between-patient factor (randomization group dummy coded as 0 = Self-directed Condition and 1 = Practice Facilitation). Fixed effects will be specified for time, randomization group, and their interaction effect (group by time). The outcome measure will be a composite index for the adoption of TASSH (defined as patients diagnosed with hypertension, who received lifestyle counseling and treatment for hypertension by the interventionists).
Additionally, the interventionists will be nested within PHCs creating a 3-level analytic model (observations nested within interventionists nested within PHCs). Random effects will be specified for PHCs and interventionists, adjusting for the clustering of measures within interventionists and interventionists within a PHC. Multi-level modeling software (SAS, Version 9, PROC MIXED) will be used to compute full information maximum likelihood (FIML) estimates of the model parameters. The PROC MIXED procedure will use an error structure that allows for the possibility of group differences in the error variances at 12 months and the serial correlations of the baseline with the 12-month outcomes. For sustainability, the analysis will be repeated as described above for adoption but will be evaluated at 24 months instead of 12 months. Adoption at 12 months will be assessed using questionnaires completed by the interventionists and sustainability at 24 months will be assessed with site interviews and visits. Levels of adoption and sustainability will be compared between the group that randomized to the PF intervention and the group randomized to the self-directed condition. The qualitative components of sustainability at 24 months will be assessed using interviews with the interventionists and clinic leadership. These interviews will be recorded, transcribed, and entered into NVIVO Version 11 for analysis.
Mediators’ outcome analysis
We will evaluate the mediators of adoption and sustainability of the PF intervention at 12 and 24 months. In particular, we will assess the extent to which inner setting variables (e.g., implementation leadership, implementation climate, and organizational culture) affect the degree of adoption of TASSH and its sustainability at 24 months. We will pay particular attention to the pathways via which this occurs. We will estimate a just-identified path model using the robust weighted least squares estimator to investigate relationships among the theoretical mediators of implementation climate, implementation leadership, organizational culture, organizational readiness to change, and external change agent support. Based on our conceptual model, we will test the direct effects from the theoretical constructs to the adoption components (individually). In addition to the direct effects, the indirect effects from each variable to adoption via inner setting variables will be estimated as the product of component direct effects and tested using bootstrapped 95% confidence intervals. Finally, we will estimate the direct effects of the predicted model of adoption on SBP reduction. Predicted probabilities of the adoption and sustainability outcomes and SBP will be calculated from path model coefficients to elucidate the magnitudes of direct and indirect effects.
Handling missing data
Although we will attempt to retain as high a fraction of participants as possible, we acknowledge that some attrition is likely, leading to missing outcome values. In the instance of missing data, the generalized linear mixed models proposed for the primary and secondary analyses incorporate an assumption of data that are missing at random (MAR) i.e., the likelihood of a value being missing depends on observable characteristics (e.g., sex or age). In sensitivity analyses, we will assess the impact of different assumptions about the missing data mechanism and will determine the robustness of trial results to these different assumptions. We will consider the use of multiple imputations of missing data as an alternative sensitivity analysis (48).
Qualitative analysis
For qualitative data analysis, semi-structured and user-testing interviews will be transcribed and entered into the qualitative software, NVivo, version 11, for organization and management of the qualitative data obtained. We will use the framework approach to qualitative data analysis, a 5- step process: (a) familiarization, (b) developing a theoretical framework, (c) indexing, (d) summarizing data in an analytical framework (in this case using CFIR constructs), and (e) data synthesis and interpretation. Following this framework, data will be independently coded by 2–3 experienced research staff to reduce the potential for bias. Inter-rater reliability will be determined and discrepancies in coded data will be resolved by consensus.
All transcripts will be coded into concepts reflecting the aims of the pre-implementation phase. For example, responses will be coded according to intervention characteristics (e.g., core elements of TASSH) likely to influence its adoption in PHCs. The identified concepts will be grouped into categories and themes uniting the categories determined. A detailed analysis of the interviews should generate a conceptual model of the barriers and facilitators of TASSH uptake and domains of a PF strategy tailored to the Nigerian healthcare system.